Cerevel Therapeutics Holdings, Inc. - Common Stock (CERE)

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQCERE) for violations of the securities laws and potential breaches of fiduciary duty on the part of its directors and management.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQCERE) for potential breaches of fiduciary duty on the part of its directors and management.

Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQCERE) (“Cerevel”) on behalf of the company’s shareholders.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQCERE) and AbbVie, Inc. (“AbbVie”) NYSE: ABBVNYSEABBV)

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQCERE) and AbbVie, Inc. (“AbbVie”) NYSE: ABBVNYSEABBV)

Revenue growth during what should be a disastrous patent cliff is encouraging.

CERE stock results show that Cerevel Therapeutics Hldg missed analyst estimates for earnings per share the second quarter of 2024.

Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed.

The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.

On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.

AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.

Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.

Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000's Phase 3 trial this year, reducing late-stage risks.

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.

AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.

BALA CYNWYD, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).

If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQCERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders.

The company is grappling with losing Humira's patent protection in 2023.

BALA CYNWYD, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.